Assess an author's data and outputs

Author review (concise)

P. A. Futreal is a high-impact cancer genomics author with multiple widely-cited landmark contributions (e.g. cancer gene census, BRAF mutational discovery, mutational signatures, intratumor heterogeneity) that shaped modern cancer genomics and translational oncology. Key representative works are listed below.

• Cancer Gene Census (2004)
• BRAF mutation discovery (2002)
• Mutational signatures (2013)

See the long review for visualizations (mutation frequencies from a BRAF sequencing dataset) and a critical appraisal of strengths and blind spots.

Author Review — P. A. Futreal (visual first)

Visual interpretation (quick)

The supplied BRAF sequencing dataset shows very high prevalence in skin (consistent with melanoma) and thyroid, and substantial representation in large intestine and ovary — broadly consistent with independent literature that BRAF V600E is common in melanoma and thyroid cancers and present in colorectal/ovarian contexts (see representative citations below).

Evidence-based strengths (with representative landmark citations)

• Foundational, high-impact contributions: Futreal is author/co-author on multiple highly-cited, field-defining works (e.g., the cancer gene census; BRAF mutation discovery; contributions to mutational-signature and pan-cancer genome characterization) that established shared resources and frameworks used widely in cancer genomics and translational oncology. Cancer Gene Census (2004)
• Translational relevance: participation in the multi-tissue BRAF sequencing and aggregation studies linked somatic mutations to potential therapeutic targets (BRAF inhibitors), underpinning later clinical translation. BRAF mutation discovery (2002)
• Methodological and conceptual influence: contributions to mutational-signature analysis and to multiregion sequencing literature advanced computational frameworks and experimental designs for dissecting tumor evolution and etiology. Mutational signatures (2013)

Key limitations, blindspots, and critical caveats

• Resource vs. mechanistic work: many high-impact outputs are curated resources, catalogs, or large-scale genomic mappings — extraordinarily valuable for the field but sometimes less focused on single-mechanism proof; such resources rely on downstream interpretation and follow-up mechanistic validation by multiple groups.
• Authorship & contribution granularity: landmark studies are large collaborations; contribution as a co-author varies in nature (conceptual, analytical, experimental). Assessing individual methodological novelty requires parsing author contributions per paper rather than inferring from overall citation counts.
• Temporal evolution of methods: early genomic screens (1990s–2000s) used Sanger/targeted sequencing and curated pipelines; later high-depth WGS/SSNV signature decomposition methods matured after those papers — some early conclusions were later refined by deeper sequencing and larger consortia data.
• Attribution uncertainties in signatures and catalogs: mutational-signature attribution is model-dependent and can misassign processes without orthogonal biochemical validation; cancer gene curation depends on evolving definitions of driver/passenger.

Representative high-quality evidence (selected) supporting influence

1. BRAF mutation discovery (2002)
2. Mutational signatures (2013)
3. Multiregion sequencing (2012)

Interpretive summary — scientific standing

Taken purely on scientific contribution and influence within cancer genomics, P. A. Futreal’s record (as a recurrent author/co-author on multiple landmark, highly-cited resources and research papers) places him among the influential leaders shaping genomic discovery and translational direction in oncology. The work is characterized by: large-scale data aggregation, resource-building (censuses/catalogs), early discovery sequencing, and contributions to conceptual frameworks (mutational signatures, tumor heterogeneity). The strengths lie in scale, reproducibility of core findings across independent cohorts, and lasting translational impact. Primary weaknesses or caveats are the collaborative nature of large consortia papers (necessitating careful attribution of specific technical innovations to individuals) and the normal evolution of interpretations as deeper data and orthogonal validations accumulate.

What evidence would substantially change this appraisal?

• Robust, reproducible refutation that key cataloged driver genes are not drivers (requires multiple independent mechanistic disproofs).
• Demonstration that methodological errors (e.g., systematic sequencing/annotation bias) materially altered major claims of the landmark resources.

Selected citations referenced in this review

• Cancer Gene Census (2004)
• BRAF mutation discovery (2002)
• Mutational signatures (2013)
• Multiregion sequencing (2012)